MCID: MYS005
MIFTS: 56

Myositis malady

Categories: Muscle diseases, Neuronal diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Myositis

About this section

Summaries for Myositis

About this section
MedlinePlus:37 Myositis means inflammation of the muscles that you use to move your body. an injury, infection, or autoimmune disease can cause it. two specific kinds are polymyositis and dermatomyositis. polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. dermatomyositis causes muscle weakness, plus a skin rash. other symptoms of myositis may include fatigue after walking or standing tripping or falling trouble swallowing or breathing doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. there is no cure for these diseases, but you can treat the symptoms. polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. nih: national institute of neurological disorders and stroke

MalaCards based summary: Myositis, also known as inflammatory disorder of muscle, is related to inclusion body myositis and myositis ossificans, and has symptoms including proximal muscle weakness, myositis and back pain. An important gene associated with Myositis is HARS (Histidyl-TRNA Synthetase), and among its related pathways are Neuroscience and tRNA Aminoacylation. The drugs chlorzoxazone and tizanidine hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and skin, and related mouse phenotypes are cardiovascular system and no phenotypic analysis.

Disease Ontology:11 A myopathy characterized by muscle inflammation.

Wikipedia:70 Myositis is a general term for inflammation or swelling of the muscles. Injury, medicines, infection, or... more...

Related Diseases for Myositis

About this section

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 338)
idRelated DiseaseScoreTop Affiliating Genes
1inclusion body myositis12.5
2myositis ossificans12.2
3focal myositis12.1
4myositis fibrosa12.1
5fibrodysplasia ossificans progressiva12.0
6bacterial myositis12.0
7viral myositis12.0
8infective myositis12.0
9fungal myositis12.0
10idiopathic eosinophilic myositis11.9
11granulomatous myositis11.9
12pyomyositis11.8
13juvenile overlap myositis11.8
14idiopathic inflammatory myopathy11.7
15dermatomyositis11.6
16polymyositis11.2
17orbital plasma cell granuloma10.8
18muscle disorders10.8
19foot drop10.8
20osseous heteroplasia, progressive10.7
21childhood type dermatomyositis10.7
22epidemic pleurodynia10.7
23autoimmune necrotizing myopathy10.7
24cataract10.6CAPN3, DYSF
25adrenal gland hyperfunction10.6DYSF, PIK3C2A
26cerebellar agenesis10.5DMD, DYSF
27vaginal tubular adenoma10.5APP, BACE1, MAPT
28angiomyolipoma10.5APP, BACE1, MAPT
29muscular dystrophy, rigid spine, 110.5DMD, TTN
30chronic intestinal vascular insufficiency10.5APP, BACE1, MAPT
31dystrophinopathies10.5CAPN3, DYSF
32miyoshi muscular dystrophy 110.5CAPN3, CHKB, DYSF
33visual snow syndrome10.4MB, PIK3C2A
34endocervical type cervical adenomyoma10.4MB, PIK3C2A
35hereditary antithrombin deficiency10.4HARS, TARS
36rippling muscle disease10.4DYSF, TTN
37myopathy, lactic acidosis, and sideroblastic anemia10.4DMD, TTN
38parkinsonism with spasticity, x-linked10.4DMD, PIK3C2A
39hyperphenylalaninemia10.4DYSF, GNE
40bethlem myopathy 110.3CAPN3, DMD, DYSF
41subendocardial myocardial infarction10.3MAPT, MB, PIK3C2A
42adrenocortical insufficiency, without ovarian defect10.3APP, MAPT
43myelodysplastic myeloproliferative cancer10.3PIK3C2A, TTN
44schindler disease10.3DMD, DYSF
45neuronal migration disorders10.3CHKB, DMD, MSTN
46macrophagic myofasciitis10.3
47gemistocytic astrocytoma10.3APP, DMD, MAPT
48creatine phosphokinase, elevated serum10.3CHKB, MB, PIK3C2A
49proliferating trichilemmal cyst10.3DMD, MB
50polyosteolysis/hyperostosis syndrome10.3AARS, CHKB, HARS, IFIH1

Graphical network of the top 20 diseases related to Myositis:



Diseases related to myositis

Symptoms for Myositis

About this section

Human phenotypes related to Myositis:

 63
id Description HPO Frequency HPO Source Accession
1 proximal muscle weakness63 HP:0003701
2 myositis63 HP:0100614

UMLS symptoms related to Myositis:


back pain, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, myalgia

Drugs & Therapeutics for Myositis

About this section

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 162)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AbataceptapprovedPhase 4, Phase 3, Phase 2192332348-12-610237
Synonyms:
CTLA4-Ig
 
CTLA4-IgG4m
CTLA4Ig
CTLA4IgG4m
2
Tenofovirapproved, investigationalPhase 4733147127-20-6464205
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-9-(2-phosphonomethoxypropyl)adenine
(R)-PMPA
147127-20-6
206184-49-8
AC-760
AC1LA9BO
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
GNA & Tenofovir
GS 1275
GS 1278
GS1278
 
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
PMPA
PMPA-(R)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
S1401_Selleck
TDF
TFV
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir disoproxil
Tenofovir disoproxil fumarate
UNII-99YXE507IL
Viread
Viread, Tenofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
3
SimvastatinapprovedPhase 4, Phase 251079902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
4
BenzocaineapprovedPhase 4, Phase 2, Phase 318921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
5
Telbivudineapproved, investigationalPhase 4853424-98-4159269
Synonyms:
1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione
1-(2-Deoxy-beta-L-ribofuranosyl)-5-methyluracil
1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
2'-Deoxy-L-thymidine
3424-98-4
AC-5632
AC1L4LJI
Beta-l-thymidine
CHEBI:17748
CHEMBL374731
CID159269
D06675
DB01265
Epavudine
I14-8810
L-DT
L-Deoxythymidine
L-Thymidine
L-dT
L-deoxythymidine
L-thymidine
 
LDT
LDT-600
LDT600
LLT
LS-186402
LS-187347
LdT
NB 02B
NV 02B
NV-02B
S1651_Selleck
Sebivo
Telbivudin
Telbivudine
Telbivudine (USAN/INN)
Telbivudine [USAN]
Tyzeka
Tyzeka (TN)
Tyzeka, Sebivo, Telbivudine
UNII-2OC4HKD3SF
ZINC00002159
beta-L-2'-Deoxythymidine
beta-L-Thymidine
6
Entecavirapproved, investigationalPhase 4180142217-69-4153941
Synonyms:
142217-69-4
2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one--water (1/1)
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
209216-23-9
6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]
9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
AB1004838
AC-1593
AC1L4BEC
Anhydrous entecavir
BMS-200475
Baraclude
Baraclude (TN)
CHEBI:473990
CHEBI:59902
CHEMBL713
CID153941
 
D04008
D07896
DB00442
ETV
Entecavir
Entecavir (INN)
Entecavir (USAN)
Entecavir (anhydrous)
Entecavir anhydrous
Entecavir hydrate
Entecavir hydrate (JAN)
Entecavirum
FT-0083013
MolPort-005-942-963
S2128_Selleck
SBB066120
SQ-34676
TL8000933
ZINC03802690
entecavir monohydrate
7
Olmesartanapproved, investigationalPhase 4126144689-24-7, 144689-63-4158781, 130881
Synonyms:
144689-24-7
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
AC1L4KLS
Benicar
Benicar HCT
C437965
CHEBI:48416
CHEMBL1516
CID158781
CPD000466337
CS-088
D05246
DE-092
HMS2051K12
 
I14-10085
L001097
LS-181800
MLS000759446
MLS001424016
MolPort-003-666-606
Olmesartan
Olmesartan (USAN/INN)
Olmesartan [USAN]
Olmesartan medoximil
Olmesartan medoxomil
Olmetec
RNH 6270
RNH-6270
SAM001246634
SMR000466337
UNII-8W1IQP3U10
Votum
olmesartan
omesartan
8
LiraglutideapprovedPhase 4315204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
9tannic acidapproved, NutraceuticalPhase 4, Phase 2, Phase 31892
10
PirfenidoneinvestigationalPhase 44953179-13-840632
Synonyms:
5-21-07-00197 (Beilstein Handbook Reference)
5-Methyl-1-phenyl-1H-pyridin-2-one
5-Methyl-1-phenyl-2(1H)-pyridone
5-Methyl-1-phenyl-2-(1H)-pyridone
5-methyl-1-phenylpyridin-2(1H)-one
5-methyl-1-phenylpyridin-2-one
53179-13-8
AC-6797
AC1L2454
AMR 69
AMR-69
BRD-K96862998-001-03-1
BRN 1526549
Bio1_000397
Bio1_000886
Bio1_001375
C093844
C12H11NO
CID40632
D01583
Deskar
EN000704
EU-0100907
Esbriet
F-647
FT-0082541
 
I01-1466
KS-5041
LS-133834
Lopac-P-2116
Lopac0_000907
MLS000860042
NCGC00015806-01
NCGC00015806-03
NCGC00015806-05
NCGC00024992-01
NCGC00024992-02
NCGC00024992-03
P 2116
P2116_SIGMA
PIRFENIDONE
Pirespa
Pirfenidona
Pirfenidona [INN-Spanish]
Pirfenidone (Deskar)
Pirfenidone (JAN/USAN/INN)
Pirfenidone [USAN:INN]
Pirfenidonum
Pirfenidonum [INN-Latin]
S-7701
SMR000326900
Tocris-1093
ZINC00001958
11Anticholesteremic AgentsPhase 4, Phase 21983
12HormonesPhase 4, Phase 3, Phase 2, Phase 113979
13Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112778
14Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112770
15Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
16Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110355
17Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122776
18Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112767
19VaccinesPhase 46428
20Lipid Regulating AgentsPhase 4, Phase 22702
21Rosuvastatin CalciumPhase 4459147098-20-2
22Hypolipidemic AgentsPhase 4, Phase 22721
23Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 4, Phase 2, Phase 31956
24AntimetabolitesPhase 4, Phase 3, Phase 211774
25Calcium, DietaryPhase 4, Phase 35525
26Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
27Anti-HIV AgentsPhase 43100
28Antiviral AgentsPhase 4, Phase 19732
29Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 24855
30Reverse Transcriptase InhibitorsPhase 41880
31Anti-Retroviral AgentsPhase 43232
32Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 14295
33beta-endorphinPhase 4, Phase 2133
34Analgesics, Non-NarcoticPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 16260
35Adrenocorticotropic HormonePhase 4, Phase 2155
36Insulin, Globin ZincPhase 4, Phase 14523
37insulinPhase 4, Phase 14524
38Melanocyte-Stimulating HormonesPhase 4, Phase 2132
39AnalgesicsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 111287
40Vasoconstrictor AgentsPhase 42027
41Antihypertensive AgentsPhase 44095
42HIV Protease InhibitorsPhase 45319
43VitaminsPhase 4, Phase 2, Phase 35095
44AngiotensinogenPhase 41161
45Angiotensin Receptor AntagonistsPhase 41173
46
Angiotensin IIPhase 4116268521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
47Angiotensin II Type 1 Receptor BlockersPhase 41078
48
protease inhibitorsPhase 45320
Synonyms:
 
protease inhibitors
49
Olmesartan medoxomilPhase 4126144689-63-4130881
Synonyms:
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate
144689-63-4
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
AC-1601
AC1L2Y71
BRD-K78485176-001-02-9
BSPBio_003491
Benevas
Benicar
Benicar (TN)
Benicar, Olmetec,Olmesartan
Berlin-Chemie Brand of Olmesartan Medoxomil
Bio-0071
C097933
CHEMBL1200692
CID130881
CS-866
CS-866DM
CS-866RN
Cs 866
D01204
DB00275
DE-092
Forest Brand of Olmesartan Medoxomil
HMS1922L15
HMS2089K18
 
HMS2093K16
I06-0025
KBio2_002490
KBio2_005058
KBio2_007626
KBio3_002711
KBioGR_001040
KBioSS_002498
KS-1182
L001061
LS-181818
MolPort-003-666-605
MolPort-005-935-047
NCGC00095136-01
NCGC00095136-02
Olmesartan medoximil
Olmesartan medoxomil
Olmesartan medoxomil (JAN/USAN)
Olmetec
Olmetec (TN)
Olvance
S1587_Selleck
SPBio_000431
SPECTRUM1505205
Sankyo Brand of Olmesartan Medoxomil
Spectrum2_000506
Spectrum3_001676
Spectrum4_000740
Spectrum5_001556
Spectrum_001944
UNII-6M97XTV3HD
50UbiquinonePhase 4, Phase 2, Phase 3139

Interventional clinical trials:

(show top 50)    (show all 144)
idNameStatusNCT IDPhase
1Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol LevelUnknown statusNCT00866229Phase 4
2Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With EntecavirUnknown statusNCT01588912Phase 4
3Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune DiseaseUnknown statusNCT00815282Phase 4
4Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesUnknown statusNCT01151644Phase 4
5Angiotensin II Blockade and Inflammation in ObesityCompletedNCT01684748Phase 4
6Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-beingCompletedNCT02255682Phase 4
7Stop Atherosclerosis in Native Diabetics StudyCompletedNCT00147251Phase 4
8Abatacept in Juvenile DermatomyositisRecruitingNCT02594735Phase 4
9Living With Statins - Interventional Exercise StudyRecruitingNCT02796378Phase 4
10Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of DermatomyositisRecruitingNCT02245841Phase 4
11The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in HumansActive, not recruitingNCT02403284Phase 4
12Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic DermatomyositisNot yet recruitingNCT02821689Phase 4
13Is Myopathy Part of Statin Therapy (IMPOSTER-16)TerminatedNCT00127335Phase 4
14Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant TacrolimusUnknown statusNCT00504348Phase 2, Phase 3
15Five-year Actively Controlled Clinical Trial in New Onset Juvenile DermatomyositisUnknown statusNCT00323960Phase 3
16Arimoclomol in Sporadic Inclusion Body MyositisCompletedNCT00769860Phase 2, Phase 3
17Treatment With TNF Blockade, Infliximab, in Patients With MyositisCompletedNCT00443222Phase 2, Phase 3
18Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedNCT02250443Phase 2, Phase 3
19Anakinra in MyositisCompletedNCT01165008Phase 2, Phase 3
20Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM PatientsCompletedNCT01925209Phase 2, Phase 3
21Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DMCompletedNCT00651040Phase 3
22Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle SymptomsCompletedNCT01032993Phase 2, Phase 3
23High Dose Cyclophosphamide for Treatment of SclerodermaCompletedNCT00501995Phase 3
24Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant RecipientsCompletedNCT00975000Phase 3
25Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye SyndromeCompletedNCT00025818Phase 3
26Scleroderma: Cyclophosphamide or Transplantation (SCOT)CompletedNCT00114530Phase 2, Phase 3
27Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)CompletedNCT00335985Phase 3
28Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.CompletedNCT00138983Phase 3
29Belimumab in MyositisRecruitingNCT02347891Phase 2, Phase 3
30Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILDRecruitingNCT01862926Phase 2, Phase 3
31An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203Active, not recruitingNCT02573467Phase 3
32Rapamycine vs Placebo for the Treatment of Inclusion Body MyositisActive, not recruitingNCT02481453Phase 2, Phase 3
33Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory MyopathyNot yet recruitingNCT02971683Phase 3
34Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)Not yet recruitingNCT02728752Phase 3
35Understanding the Pathogenesis and Treatment of Childhood Onset DermatomyositisTerminatedNCT00035958Phase 2, Phase 3
36Statins for the Early Treatment of SepsisUnknown statusNCT00528580Phase 2
37Abatacept Treatment in Polymyositis and DermatomyositisUnknown statusNCT01315938Phase 2
38Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedNCT01423110Phase 2
39Alemtuzumab to Treat Sporadic Inclusion Body MyositisCompletedNCT00079768Phase 2
40Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisCompletedNCT00774462Phase 2
41Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory MyopathiesCompletedNCT00001261Phase 2
42A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or MyositisCompletedNCT00979654Phase 2
43Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)CompletedNCT00106184Phase 2
44The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory MarkersCompletedNCT00805870Phase 2
45Efficacy and Tolerability of BAF312 in Patients With PolymyositisCompletedNCT01801917Phase 2
46Methimazole to Treat Polymyositis and DermatomyositisCompletedNCT00001421Phase 2
47Infliximab (Remicade ) to Treat Dermatomyositis and PolymyositisCompletedNCT00033891Phase 2
48Acthar in Treatment of Refractory Dermatomyositis and PolymyositisCompletedNCT01906372Phase 2
49Safety and Effectiveness of h5G1.1-mAb for DermatomyositisCompletedNCT00005571Phase 2
50Efficacy of an Individual Rehabilitation Program in Polymyositis and DermatomyositisCompletedNCT01415219Phase 2

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

About this section

Genetic tests related to Myositis:

id Genetic test Affiliating Genes
1 Myositis26

Anatomical Context for Myositis

About this section

MalaCards organs/tissues related to Myositis:

35
Bone, Testes, Skin, T cells, Skeletal muscle, Lung, Tongue

Animal Models for Myositis or affiliated genes

About this section

MGI Mouse Phenotypes related to Myositis:

40 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053859.2AARS, CAPN3, DMD, GNE, MAPT, MB
2MP:00030128.9APP, BACE1, CAPN3, DMD, DYSF, MAPT
3MP:00053868.8AARS, APP, BACE1, CHKB, DMD, DYSF
4MP:00053848.6AARS, APP, BACE1, BACE2, DMD, IFIH1
5MP:00053698.5AARS, APP, BACE1, CAPN3, CHKB, DMD
6MP:00053768.3APP, BACE1, CAPN3, CHKB, DMD, DYSF
7MP:00053788.1AARS, APP, BACE1, BACE2, CAPN3, DMD
8MP:00107687.5AARS, APP, BACE1, BACE2, DMD, FBL

Publications for Myositis

About this section

Articles related to Myositis:

(show top 50)    (show all 1906)
idTitleAuthorsYear
1
Immune-array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity across the Myositis Spectrum. (28086002)
2017
2
Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis. (27048400)
2016
3
Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab. (27920658)
2016
4
Mosaic Tetrasomy 9p: A Mendelian Condition Associated With Pediatric-Onset Overlap Myositis. (26216333)
2015
5
Myositis ossificans of the left medial pterygoid muscle: case report and review of the literature of myositis ossificans of masticatory muscles. (24624256)
2014
6
Orbital myositis in BehAset's disease. (24326194)
2013
7
Primary respiratory failure due to inclusion body myositis: think outside the box. (23589953)
2013
8
A mixed-type autoimmune hemolytic anemia with immune thrombocytopenia related with myositis and post-transplantation lymphoproliferative disorder. (24013519)
2013
9
188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. (24268584)
2013
10
Dengue Viral Myositis Complicated with Rhabdomyolysis and Superinfection of Methicillin-Resistant Staphylococcus aureus. (23476836)
2013
11
Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. (23658122)
2013
12
Percutaneous endoscopic gastrostomy feeding--a life-saving intervention in SSc-myositis overlap with pharyngeal dysfunction. (22461389)
2012
13
Myositis ossificans of the forearm after yoga. (22856477)
2012
14
Morphoea with myositis: a rare association. (22937437)
2011
15
Vaccination-induced myositis with intramuscular sterile abscess formation. (21479517)
2011
16
Myositis ossificans around shoulder following military training programme. (22144755)
2011
17
Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. (21457520)
2011
18
Myositis ossificans circumscripta of the leg after an old gunshot injury. (21183381)
2011
19
Measurement of activation of the endoplasmic reticulum stress response in autoimmune myositis. (21266232)
2011
20
Mixed connective tissue disease presenting as a peculiar myositis with poor muscle regeneration. (20890626)
2011
21
Myositis ossificans of the supinator muscle causing posterior interosseous nerve palsy: a case report. (20672400)
2010
22
Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. (19291799)
2009
23
Recurrent orbital myositis with radiological feature mimicking thyroid eye disease in a patient with Crohn's disease. (19929661)
2009
24
Voriconazole-associated myositis. (20009971)
2009
25
Inclusion body myositis and HIV infection. (18641890)
2008
26
Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation". (18626972)
2008
27
Tuberculous myositis: an unusual presentation of extrapulmonary tuberculosis. (17332912)
2007
28
Bilateral and recurrent myositis ossificans in an athlete: a case report and review of treatment options. (16442986)
2006
29
Inclusion body myositis: an underdiagnosed myopathy of older people. (16364943)
2006
30
Camptocormia associated with focal myositis in multiple-system atrophy. (16211611)
2006
31
Infection and musculoskeletal conditions: Infectious myositis. (17127198)
2006
32
Sporadic inclusion body myositis: morphology, regeneration, and cytoskeletal structure of muscle fibres. (15146016)
2004
33
Insulin-like growth factor I in inclusion-body myositis and human muscle cultures. (15217093)
2004
34
Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. (12667656)
2003
35
Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. (12124873)
2002
36
Update on myositis-specific and myositis-associated autoantibodies. (11092195)
2000
37
Focal myositis in the mylohyoid muscle of an adult. (10709172)
2000
38
Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis. (9596410)
1998
39
T-cell heterogeneity in muscle lesions of inclusion body myositis. (9600712)
1998
40
Hepatitis C and inclusion body myositis. (8792712)
1996
41
Myositis ossificans progressiva: a 10-year follow-up on a patient treated with etidronate disodium. (7734885)
1994
42
Myositis ossificans of medial pterygoid muscle. A cause for temporomandibular joint ankylosis. (1603562)
1992
43
Inclusion body myositis: analysis of 32 cases. (1331441)
1992
44
HLA and myositis ossificans circumscripta. (3798051)
1986
45
Bacterial myositis and pyomyositis. (6481673)
1984
46
Acute bacterial myositis caused by Vibrio vulnificus. (7241733)
1981
47
Myositis ossificans localisata as a complication of tetanus. (525320)
1979
48
Myositis ossificans: evolution to osteogenic sarcoma. Report of a histologically verified case. (5228630)
1967
49
Myositis Ossificans Progressiva. (19994086)
1961
50
Traumatic proliferations of fibrocartilage with ossification in the genesis of spondylitis deformans and myositis ossificans. (18932588)
1948

Variations for Myositis

About this section

Expression for genes affiliated with Myositis

About this section
Search GEO for disease gene expression data for Myositis.

Pathways for genes affiliated with Myositis

About this section

Pathways related to Myositis according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.4APP, BACE1, MAPT, NCAM1
2
Show member pathways
9.4AARS, HARS, NARS, TARS
39.2APP, BACE1, BACE2, MAPT

GO Terms for genes affiliated with Myositis

About this section

Cellular components related to Myositis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Z discGO:003001810.2CAPN3, DMD, TTN
2endosomeGO:00057689.7APP, BACE1, BACE2, DYSF
3cell surfaceGO:00099869.2APP, BACE1, BACE2, DMD, NCAM1
4extracellular exosomeGO:00700627.8AARS, APP, DYSF, FBL, MB, NARS
5cytosolGO:00058297.4AARS, APP, CAPN3, CHKB, DMD, GNE

Biological processes related to Myositis according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1axo-dendritic transportGO:000808810.5APP, MAPT
2response to muscle activityGO:001485010.4CAPN3, MSTN
3beta-amyloid metabolic processGO:005043510.1BACE1, BACE2
4muscle organ developmentGO:00075179.9CAPN3, DMD, MSTN
5membrane protein ectodomain proteolysisGO:00065099.6BACE1, BACE2
6muscle cell cellular homeostasisGO:00467169.6CAPN3, DMD, MSTN
7tRNA aminoacylation for protein translationGO:00064189.4AARS, HARS, NARS, TARS

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1aspartic-type endopeptidase activityGO:000419010.2BACE1, BACE2
2structural constituent of muscleGO:00083079.8CAPN3, DMD, TTN
3ATP bindingGO:00055248.2AARS, CHKB, GNE, HARS, IFIH1, NARS

Sources for Myositis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet